Prediction of Post Percutaneous Coronary Intervention Myocardial Ischaemia

Myocardial revascularisation in patients with stable chronic angina is performed with the aim of reducing cardiovascular death, reducing myocardial infarction (MI) and relieving angina symptoms. However, contrary to expectations, modern therapy with percutaneous coronary intervention (PCI) has not had a significant impact on hard outcomes.1–5 Indeed, as also summarised in a recently published meta-analysis,6 PCI in stable angina patients does not reduce cardiovascular death or MI.

Statins: Practical Considerations – A Review

Statins are currently the most efficacious and widely prescribed lipid-lowering medications.1 Numerous randomised controlled trials across a spectrum of baseline atherosclerotic cardiovascular disease (ASCVD) risk show that a 1.0 mmol/L (~40 mg/dL) reduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy is associated with an overall 21 % reduction in major vascular events and 20 % reduction in coronary death.2 Prescribing behaviour of statins has dramatically changed in the last 20 years, with a sixfold increase of statin use in

The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology

Elevated levels of low-density lipoprotein cholesterol (LDL-C) have long been established as one of the most important risk factors for developing coronary artery disease (CAD) and other forms of atherosclerotic cardiovascular disease (CVD).1,2 Targeting LDL-C reduction has been effective in lowering cardiovascular risk.3,4 The use of HMGCoA reductase inhibitors (statins) for both primary and secondary cardiovascular disease prevention has become first-line therapy and has resulted in reduction of cardiovascular (CV) events and overall mortality.3 More recen